Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

PHASE3CompletedINTERVENTIONAL
Enrollment

430

Participants

Timeline

Start Date

December 15, 2015

Primary Completion Date

August 30, 2016

Study Completion Date

August 1, 2017

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)

2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.

Trial Locations (32)

13760

GSK Investigational Site, Endwell

13901

GSK Investigational Site, Binghamton

15401

GSK Investigational Site, Uniontown

16506

GSK Investigational Site, Erie

16508

GSK Investigational Site, Erie

19107

GSK Investigational Site, Philadelphia

21045

GSK Investigational Site, Columbia

21075

GSK Investigational Site, Elkridge

23606

GSK Investigational Site, Newport News

28209

GSK Investigational Site, Charlotte

29303

GSK Investigational Site, Spartanburg

29464

GSK Investigational Site, Mt. Pleasant

35802

GSK Investigational Site, Huntsville

44122

GSK Investigational Site, Cleveland

54449

GSK Investigational Site, Marshfield

54701

GSK Investigational Site, Eau Claire

66219

GSK Investigational Site, Lenexa

67114

GSK Investigational Site, Newton

67207

GSK Investigational Site, Wichita

83642

GSK Investigational Site, Boise

84041

GSK Investigational Site, Layton

84095

GSK Investigational Site, South Jordan

84109

GSK Investigational Site, Salt Lake City

84121

GSK Investigational Site, Salt Lake City

94015

GSK Investigational Site, Daly City

94612

GSK Investigational Site, Oakland

95032

GSK Investigational Site, Los Gatos

95405

GSK Investigational Site, Santa Rosa

95661

GSK Investigational Site, Roseville

97330

GSK Investigational Site, Corvallis

04210

GSK Investigational Site, Auburn

01752

GSK Investigational Site, Marlborough

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02581410 - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier | Biotech Hunter | Biotech Hunter